ABSTRACT
No disponible
Subject(s)
Humans , Male , Adult , Aged , Aged, 80 and over , Thrombocytopenia/chemically induced , Heparin/adverse effects , Thrombocytopenia/epidemiology , Cohort Studies , Pneumonia, Viral/diagnosis , Thrombocytopenia/prevention & control , Heparin/administration & dosage , Heparin, Low-Molecular-Weight/administration & dosage , Heparin, Low-Molecular-Weight/adverse effects , Retrospective Studies , BetacoronavirusSubject(s)
Anticoagulants/adverse effects , Betacoronavirus , Coronavirus Infections/blood , Heparin, Low-Molecular-Weight/adverse effects , Pneumonia, Viral/blood , Thrombocytopenia/chemically induced , Thrombophilia/drug therapy , Aged , Aged, 80 and over , COVID-19 , Coronavirus Infections/complications , Female , Humans , Incidence , Male , Middle Aged , Pandemics , Pneumonia, Viral/complications , SARS-CoV-2 , Thrombocytopenia/epidemiology , Thrombophilia/etiologySubject(s)
Blood Coagulation , Warfarin , Drug Interactions , Humans , International Normalized RatioABSTRACT
OBJECTIVE: Our aim was to determinate the acenocoumarol dose requirement in highly sensitive geriatric patients, based on a minimum of genotype (VKORC1 and CYP2C9) data. METHODS: We used a Gaussian kernel density estimation test to identify patients highly sensitive to the drug and PHARMACHIP®-Cuma test (Progenika Biopharma, SA, Grifols, Spain) to determine the CYP2C9 and VKORC1 genotype. RESULTS: All highly sensitive geriatric patients were taking ≤5.6 mg/week of acenocoumarol (AC), and 86% of these patients presented the following genotypes: CYP2C9*1/*3 or CYP2C9*1/*2 plus VKORC1 A/G, CYP2C9*3/*3, or VKORC1 A/A. CONCLUSION: VKORC1 A and CYP2C9*2 and/or *3 allelic variants extremely influence on AC dose requirement of highly sensitive geriatric patients. These patients display acenocoumarol dose requirement of ≤5.6 mg/week.
